ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors November 19, 2024
Xenetic Biosciences Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform November 13, 2024
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize SC ENHERTU® Enabled by Alteogen’s Hybrozyme™ Technology November 12, 2024
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda November 5, 2024
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Gen Cancer Biotherapeutics November 5, 2024
Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals November 5, 2024
Revitope Enters into a License Agreement with Genmab for Next-gen T Cell Engagement Technology November 5, 2024
Ryvu Therapeutics to Collaborate with nCage Therapeutics on the Development of a Next-Gen ADC Platform November 5, 2024
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture October 29, 2024
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a MSA for n.c.a. Lutetium-177 October 22, 2024
AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and Manufacture 177Lu-BetaBart Radioantibody for Treatment of Multiple Solid Tumors October 22, 2024
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche October 22, 2024
Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology October 22, 2024
Nona Biosciences announced a strategic collaboration with OverT Bio to develop next-generation cell therapies for solid tumors October 15, 2024
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into 1L HCC Pivotal Trial October 15, 2024
Exelixis and Merck to Evaluate Zanzalintinib in Combination With KEYTRUDA in Head and Neck Cancer and in Combination With WELIREG in RCC October 15, 2024
